Article
Ensysce Biosciences Enrolls 50% Of Subjects Targeted For Interim Review In Phase 3 Trial Of PF614
~ Engineered to Deliver Potent Pain Relief with Built-In Abuse Protection ~
Comments
- No comments yet. Be the first to comment!